DigestRedComo funciona
Red
/
Empresas
Sa
No verificado

Sarepta Therapeutics, Inc.

Sobre qué escribimos

BiotecnologíaCienciaFarmacéuticaMedicina - VariosSalud

62 Comunicados de prensa

Ver todos los comunicados de prensa
23/01/2026
Salud
Higiene alimentaria
Biotecnología
Ciencia
Farmacéutica
Web y redes sociales
Telefonía
Eventos
Sarepta Therapeutics to Report 3-Year Topline Data from EMBARK Study of ELEVIDYS Gene Therapy in Ambulatory Individuals with Duchenne Muscular Dystrophy
Fuente
Sarepta Therapeutics, Inc.
Editor
Business Wire
1.00
0
12/01/2026
Salud
Biotecnología
Medicina - Varios
Sanidad
Farmacéutica
Eventos
Mercado de valores
Sarepta Reports Preliminary* Fourth Quarter and Full-Year 2025 Net Product Revenues
Fuente
Sarepta Therapeutics, Inc.
Editor
Business Wire
1.00
0
07/01/2026
Industria
Farmacéutica
Biotecnología
Salud
Medicina - Varios
Sarepta Therapeutics Announces Submission of Clinical Trial Application for SRP-1005, its Investigational Treatment for Huntington’s Disease
Fuente
Sarepta Therapeutics, Inc.
Editor
Business Wire
1.00
0
05/01/2026
Biotecnología
Salud
Farmacéutica
Medicina - Varios
Web y redes sociales
Eventos
Sarepta Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Fuente
Sarepta Therapeutics, Inc.
Editor
Business Wire
1.00
0
31/12/2026
Mercado de valores
Finanzas
Ciencia
Biotecnología
Farmacéutica
Salud
Medicina - Varios
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Fuente
Sarepta Therapeutics, Inc.
Editor
Business Wire
1.00
0
11/12/2025
VIH, SIDA y enfermedades autoinmunes
Biotecnología
Salud
Sarepta Therapeutics Announces Refinancing of Approximately $291 Million of 1.25% Convertible Senior Notes due 2027
Fuente
Sarepta Therapeutics, Inc.
Editor
Business Wire
1.00
0
25/11/2025
Industria
Ciencia
Higiene alimentaria
Biotecnología
Medicina - Varios
Salud
Farmacéutica
Sarepta Announces Approval to Begin ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne
Fuente
Sarepta Therapeutics, Inc.
Editor
Business Wire
1.00
0
24/11/2025
Industria
Ciencia
Higiene alimentaria
Medicina - Varios
Biotecnología
Sanidad
Salud
Farmacéutica
Sarepta Provides Progress Update for SRP-1003, its Investigational siRNA treatment for Myotonic Dystrophy Type 1
Fuente
Sarepta Therapeutics, Inc.
Editor
Business Wire
1.00
0
14/11/2025
Industria
Salud
Higiene alimentaria
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Sarepta Announces FDA’s Approval of Updated ELEVIDYS Prescribing Information
Fuente
Sarepta Therapeutics, Inc.
Editor
Business Wire
1.00
0
03/11/2025
Biotecnología
Salud
Farmacéutica
Medicina - Varios
Web y redes sociales
Telefonía
Mercado de valores
Sarepta Therapeutics Announces Third Quarter 2025 Financial Results and Recent Corporate Developments, Including Completion of Its Confirmatory Study, ESSENCE
Fuente
Sarepta Therapeutics, Inc.
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0